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Background and Purpose. Intravenous thrombolysis (IVT) is an approved treatment 
for anterior (ACS) and posterior (PCS) circulation stroke. However, no randomized-
controlled trial has investigated safety and efficacy of IVT according to stroke territory, 
although PCS is assumed to differ from ACS in many ways. We aimed to compare the 


























Methods. Prospectively collected data of 883 consecutive patients with acute ischemic 
stroke (788 ACS, 95 PCS) treated with IVT in three Swiss stroke centers were 
analyzed. Presenting characteristics, symptomatic intracranial hemorrhage (sICH), 
mortality and favorable outcome (modified Rankin scale 0 or 1) at 3 months were 
compared between patients with PCS and ACS.  
 
Results. As compared to patients with ACS, those with PCS were younger (mean age 
63 vs. 67 years, p=0.012) and had a lower mean baseline National Institutes of Health 
Stroke Scale score (9 vs. 12, p<0.001). Patients with PCS less often suffered sICH (0% 
vs. 5%, p=0.026) and had more often a favorable outcome (66% vs. 47%, p<0.001). 
Mortality was similar in the two groups (PCS, 9%; ACS, 13%; p=0.243). After 
multivariable adjustment, PCS was an independent predictor of lower sICH frequency 
(p=0.001), whereas stroke territory was associated neither with favorable outcome 
(p=0.177) nor with mortality (p=0.251). 
 
Conclusion. Our study suggests that PCS is associated with a lower risk of sICH after 
IVT as compared with ACS, while favorable outcome and mortality were similar in the 
two stroke territories.    



















Intravenous thrombolysis (IVT) is an approved treatment of acute ischemic stroke in 
anterior (ACS) and posterior (PCS) cerebral circulation. However, PCS differs from 
ACS in stroke etiology and outcome, as PCS is more often due to atherosclerosis,1-2 
and prognosis is assumed to be worse with a higher morbidity and mortality,3 the latter 
reaching up to 54% after basilar artery occlusion.4 In spite of these presumed 
differences, knowledge about safety and efficacy of IVT in PCS is sparse for several 
reasons: (1) no randomized, controlled trial or phase IV study has investigated safety 
and efficacy of IVT according to stroke territory;5-10 (2) just 5% of patients from the 
National Institutes of Neurological Diseases and Stroke (NINDS) study had PCS, 
although approximately 20-25% of all ischemic strokes are localized in the posterior 
circulation;5, 11-12 (3) The European Cooperative Acute Stroke Study (ECASS) I and II 
trials included only patients with hemispheric stroke syndromes,6-7 whereas the 
Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke 
(ATLANTIS) and the ECASS III trials did not report on the number of patients with 
PCS.8-9, 13 
We undertook this multicenter, observational study to compare safety and clinical 
outcome of IVT according to stroke territory. 
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We studied prospectively collected data of consecutive patients with acute ischemic 
stroke who underwent IVT with alteplase, but no other or additional thrombolytic 
treatment in the stroke centers of the University Hospitals Basel, Bern and Zurich from 
June 1998 to December 2008. Baseline investigations included neurologic and physical 
examination, assessment of stroke severity by using the National Institutes of Health 
Stroke Scale (NIHSS),14 routine blood analysis, 12-lead electrocardiography (ECG), 
brain computed tomography (CT) and/or magnetic resonance imaging (MRI). The 
following variables were ascertained: age, gender, baseline NIHSS score, vascular risk 
factors according to predefined criteria,15 atrial fibrillation, history for coronary artery 
disease, antithrombotic medication, time to treatment, stroke etiology according to the 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria,16 blood pressure and 
blood glucose values. Thrombolysis was applied according to current guidelines by 
using intravenous alteplase 0.9 mg/kg to a maximum of 90 mg, ten percent of the total 
dose given as a bolus and the remaining dose in the next hour.17 Prestroke modified 
Rankin Scale (mRS) score >1 was no reason for exclusion. All patients treated with IVT 
were admitted to intermediate or intensive care units for at least 24 hours. The centers 
Basel and Zurich treated patients primarily with IVT, whereas the center Bern 
performed more intra-arterial and/or mechanical thrombolyses, especially in patients 
with basilar artery occlusion. All centers used the 3-hour time window for IVT. The 
investigators in Zurich extended the time window to 4.5 hours from March 2002 
onwards, while this was the case in Bern and Basel from October 2008 onwards. The 
rationale was the pooled analysis by Hacke and colleagues presented at the 27th 
International Stroke Conference in February 2002 (San Antonio, Texas) and the 
ECASS III trial published in September 2008, respectively.13, 18  
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PCS was defined as a symptomatic infarct in the territory of the vertebral, the cerebellar 
or the posterior cerebral arteries or the basilar artery.1 ACS was defined as a 
symptomatic infarct in the territory of the middle or anterior cerebral artery or both. 
Lesions that were asymptomatic or not congruous with the clinical presentation were 
not considered. The classification of stroke territory was performed by one experienced 
senior stroke physician in each center (Basel, STE; Bern, MA; Zurich, RWB) by using 
both clinical and radiological findings.  
 
Outcome parameters 
All intracranial hemorrhages (ICH) were ascertained on follow-up CT or MRI obtained 
within 48 hours after IVT and additional scans in case of clinical deterioration. 
Symptomatic intracranial hemorrhage (sICH) was defined as any intracranial bleed 
temporally related to a neurological deterioration (NINDS criteria).5 In addition, we also 
used the more conservative definition from the ECASS II trial.7 Clinical outcomes were 
all-cause mortality and the level of independence measured by mRS score at 3 
months, with favorable outcome defined as a score of 0-1, and unfavorable as a score 
of 2-6. The mRS scores were assessed by certified neurologists by clinical examination 
or structured telephone interview with the patient or caregiver.  
 
Statistical analysis 
Normally distributed data were expressed as mean  standard deviation (SD) and 
compared using t-test. The two groups (IVT treatment in anterior versus IVT treatment 
in posterior circulation stroke) were compared using the Mann-Whitney test for 
continuous variables and the chi-square or Fisher exact test (the latter if some 
expected counts in the two-by-two table were too low) for dichotomous variables. 
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Multiple logistic regression analyses were performed to assess the joint effects of the 
affected territory (anterior versus posterior) and the other predictors on the outcome 
parameters sICH, mortality and favorable outcome. In a first step, the influence of every 
single potential predictor on the outcome parameters was evaluated using univariate 
logistic regression analysis. The parameters examined were age, admission NIHSS 
score, time to treatment, systolic and diastolic blood pressure, blood glucose levels on 
admission (continuous variables), patients gender, arterial hypertension, smoking 
status, diabetes mellitus, hypercholesterolemia, coronary artery disease, atrial 
fibrillation, diabetes mellitus and medication with antiplatelets or anticoagulants at 
stroke onset (categorical variables). In a second step, a multivariate logistic regression 
analysis was performed, including all potential predictors with a p-value < 0.2 from 
univariate analyses into the model. The parameter stroke territory (ACS or PCS) was 
forced in both models. For evaluating the association of stroke territory with sICH in 
logistic regression model, we used 1000 Bootstrap samples to estimate the standard 
error of the regression coefficients. Significance was declared at p<0.05 level. IBM 






























Between June 1998 to December 2008, 892 consecutive patients at three centers 
underwent IVT for acute ischemic stroke (Basel, n=359; Berne, n=116; Zurich, n=468). 
Nine of the 892 patients were excluded, because the affected vascular territory 
remained unclear (n=9). Of the 883 patients included, 95 (11%) suffered PCS and 788 
(89%) ACS. No patient showed combined clinical and radiological findings of both ACS 
and PCS. Baseline characteristics, stroke severity and etiology of the two groups are 
shown in Table 1. Patients with PCS were younger (63 vs. 67 years, p=0.012) and had 
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lower mean NIHSS scores (9 vs. 12, p<0.001), whereas the other characteristics did 
not differ between the two groups. Basilar artery occlusion was diagnosed in 10 of 95 




























At 3 months, clinical outcome was available in 878 (99%) and sICH classification in 877 
(99%) of the included 883 patients. Five (<1%) patients were lost to follow-up, one with 
PCS and 4 with ACS.  
Using the NINDS criteria, a total of 36 (4%) patients suffered a sICH, and 10 of these 
were fatal. Symptomatic ICH occurred in 5% of patients with ACS, but in none of 
patients with PCS (p=0.026) (Table 2). Multivariate logistic regression analyses 
identified atrial fibrillation (p=0.019), antiplatelet medication (p=0.025) and diastolic 
blood pressure (p=0.029) as independent predictors of sICH. With respect to the lack of 
sICH in PCS, we applied the bootstrap method for estimating the standard error of the 
regression coefficients. When assessing the joint effects of stroke territory, atrial 
fibrillation, antiplatelet medication and diastolic blood pressure on sICH, we identified a 
strong association between stroke territory and sICH (p=0.001) independent from the 
other predictors (Table 2). Applying the ECASS II criteria, sICH was observed in 26 of 
883 (3%) patients, all of which occurred in ACS. The statistical difference was less 
pronounced (p=0.049), but still significant in logistic regression analysis by using the 
bootstrap method (p=0.001). 
A total of 108 (12%) patients died during the three month follow-up period. Mortality 
did not significantly differ between the two groups (PCS, 9%; ACS, 13%; p=0.243) 
(Table 2). Multivariate logistic regression analyses identified age (p<0.001), NIHSS 
score (p<0.001) and blood glucose (p=0.001) as independent predictors of mortality. 
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No association between stroke territory and mortality was observed after adjusting for 










A favorable outcome was observed in 426 (49%) patients. Favorable outcome 
occurred more often in patients with PCS (66%) as compared to those with ACS (47%, 
p<0.001) (Table 2). Multivariate logistic regression analyses showed NIHSS score 
(p<0.001), blood glucose (p<0.001), age (p=0.006), antiplatelet medication (p=0.008), 
and anticoagulation (p=0.022) to be independently associated with favorable outcome. 
Stroke territory no longer predicted favorable outcome after adjustment for these 
predictors (p=0.177) (Table 2). 



























To our best knowledge, this is the largest series assessing the safety and clinical 
outcome of IVT for PCS in comparison to ACS. Few studies have examined IVT in 
patients with PCS; most of them had a small sample size (range of 9 to 12 patients)19-21 
or were restricted to patients with basilar artery occlusion.4, 22 
The rate of patients with PCS (11%) was lower than reported in other studies, which 
may be explained by the following reason: our study excluded patients with PCS who 
received endovascular treatment or conservative therapy only, the latter being the case 
in 31% of patients in the BASICS registry.4 Furthermore, patients with PCS might have 
more (relative) contraindications for IVT such as National Institute of Health (NIHSS) 
score ≤4 points or fluctuating stroke symptoms.5, 23-24 
The main finding of the present study was the lack of sICH in patients with PCS; 
after multivariable adjustment, PCS was associated with a lower sICH risk. In line with 
our findings, a previous study reported a significantly lower rate of hemorrhagic 
transformations after IVT for basilar artery occlusions as compared to middle cerebral 
artery occlusions and no sICH in basilar artery occlusions.25 Older age, history of 
diabetes, aspirin pre-treatment, high NIHSS score at baseline, high systolic blood 
pressure at presentation and high baseline blood glucose have been described as 
independent predictors of sICH following IVT.26 In the present study, the frequency of 
diabetes mellitus and baseline blood glucose levels were similar in patients with PCS 
and ACS. Patients with PCS had significantly lower baseline NIHSS scores as 
compared to those with ACS in the present study. A similar difference in NIHSS 
baseline scores was reported in two other studies.23-24 This may partly be explained by 
the fact that the NIHSS has limitations in the assessment of stroke severity in PCS, as 
it is highly weighted toward deficits in ACS such as aphasia and hemiparesis, whereas 
signs of PCS including bulbar deficits and ataxia receive fewer points.27 Furthermore, 
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NIHSS in PCS does not correlate with volume of ischemic lesion and lesion volume in 
PCS does not predict outcome,28-29 which is in contrast to ACS.30 Thus, we believe that 
the observed differences in NIHSS scores between patients with PCS and ACS may 
rather be related to shortcomings of the NIHSS. The age difference between the two 
patient groups was statistically significant but unlikely to account for such a pronounced 
discrepancy in the sICH rates between stroke territories. Smaller infarct volumes may 
be a reason for lower sICH rates in PCS; however, the reason for this remains 
hypothetical and we do not have any data about the ischemic or infarct volumes in both 
territories. From anatomical point of view, one argument might be the difference in 
vessel calibers as especially the brainstem is nourished by small endarteries. Collateral 
flow through the posterior communicating or the cerebellar arteries may lead to a 
slower evolution of irreversible ischemia in PCS with proximal artery occlusion.31 
However, there are currently no anatomic nor clinical-epidemiological studies to support 




























 In our study, mortality between PCS and ACS did not differ significantly in univariate 
and multivariate analyses. Favorable clinical outcome following IVT was more frequent 
in patients with PCS as compared to those with ACS in univariate analysis (p<0.001). 
The association of favorable outcome with PCS was no longer significant after 
multivariable adjustment, however (p=0.177). We are not aware of other studies that 
assessed the outcome after IVT according to stroke territory, thus no comparisons to 
existing literature can be undertaken. 
The present study has several limitations. First, comparisons of stroke severity 
between PCS and ACS by using the NIHSS may not be quite accurate, as discussed 
above. Still, this drawback is currently inevitable in the absence of an alternative 
established evaluation tool. Second, a bias in patient selection is probable in view of a 
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multi-center study with different treatment preferences. A total of 631 patients with 
ischemic stroke underwent intra-arterial and/or mechanical thrombolysis during the 
study period at the three centers. Of these 631 patients, 116 had PCS and 515 ACS. 
Some patients with severe basilar artery occlusion may have been excluded due to 
endovascular treatment. On the other hand, this bias might be counterbalanced by the 
exclusion of severe ACS with middle cerebral artery occlusion, either due to treatment 
with intraarterial thrombolysis or ultrasound enhanced IVT. Third, we were not able to 
assess early recanalization rates and infarct volumes, which might have additionally 
influenced the sICH risk. The number of patients with PCS was small precluding 
definite conclusions on outcome differences between both stroke territories. Number of 
patients with prestroke mRS >1 would be valuable for interpretation of the results with 
respect to clinical outcome, the latter defined as mRS score 0-1 at 3 months. 
Unfortunately, we did not systematically evaluate the prestroke mRS in this study. 



























In conclusion, our study suggests that PCS is associated with a lower risk of sICH 
after IVT as compared with ACS, while favorable outcome and mortality were similar in 








Table 1. Baseline Characteristics of 95 Patients with Posterior Circulation Stroke and 

















Male sex [%] 62.1  62.8  0.892 
Mean age ± SD [years] 62.9 ± 15.1  66.9 ± 14.3 0.012* 
Hypertension [%] 62.1 63.1 0.854 
Current smoking [%] 25.3  24.8  0.918 
Diabetes mellitus [%] 16.0 13.6 0.528 
Hypercholesterolemia [%] 46.4  38.7  0.171 
Antiplatelet medication at stroke onset [%] 38.9 36.1 0.584 
Anticoagulation at stroke onset [%] 1.1  2.4 0.714† 
Coronary artery disease [%] 19.1 18.0 0.793 
Atrial fibrillation [%] 17.0 24.6 0.102 
Mean NIHSS score ± SD 9.3 ± 7.9 12.2 ± 5.9 <0.001* 
Time to treatment ± SD  169.0 ± 54.5 160.0 ± 40.0 0.243* 
Mean systolic blood pressure ± SD [mm Hg] 152.8 ± 24.7  155.6 ± 24.9  0.211* 
Mean diastolic blood pressure ± SD  [mm Hg] 85.9 ± 14.7  88.1 ± 16.4  0.210* 
Mean blood glucose ± SD [mmol/L] 6.9 ± 2.6  6.9 ± 2.4  0.890* 
Cause of stroke   
     Large artery atherosclerosis [%] 15.2 12.9 
     Cardiac embolism [%] 43.5 47.8 
     Small artery disease [%] 8.7 4.3 
     Other determined etiology [%] 6.5 9.2 
     Undetermined etiology [%] 26.1 25.9 
0.331 
NIHSS denotes National Institutes of Stroke Scale, IVT intravenous thrombolysis, and SD standard deviation 
P-values apply to chi-square tests unless otherwise indicated.  
* Mann-Whitney test, † Fisher exact test
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Table 2. Symptomatic Intracranial Hemorrhage, Mortality and Favorable Outcome in Patients 
 




Symptomatic ICH Mortality Favorable outcome 
 
[n/N (%)] P  Value Unadjusted 
P  Value 
Adjusted [n/N (%)] 
P  Value 
Unadjusted 
P  Value 
Adjusted [n/N (%)] 
P  Value 
Unadjusted 
P  Value 
Adjusted 
Posterior Circulation Stroke 0/93 (0) 8/94 (9) 62/94 (66) 
Anterior Circulation Stroke 36/784 (5) 









Symptomatic intracranial hemorrhage (ICH) refers to NINDS criteria. P-values apply to chi-square tests unless otherwise indicated.  
* Fisher exact test 
† adjusted for atrial fibrillation, antiplatelet medication and diastolic blood pressure in logistic regression analysis (bootstrap method) 
‡ adjusted for age, NIHSS score and blood glucose in logistic regression analysis 
§ adjusted for NIHSS score, blood glucose, age, antiplatelet medication, and anticoagulation in logistic regression analysis
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